JINJIA(SZ:002191)2022-12-06 11:28Group 1: Company Overview and Leadership - The company has invested 3 million RMB to establish a gene correction technology system for Mediterranean anemia based on CRISPR/Cas9 technology [3] - The project leader, Jiang Shan, has extensive experience in the industry, having worked at renowned institutions such as Peking University Shenzhen Hospital and BGI [3] - Huang Junjie, a key researcher, published the world's first paper on using CRISPR technology to correct pathogenic genes in human embryos in April 2015, significantly impacting the scientific community [3] Group 2: Strategic Plans in Health Industry - The company plans to focus on the health aging and cancer prevention sectors, leveraging its existing resources and expertise [4] - The health industry has a large market scale, and the company aims to utilize its capital integration advantages through investments and partnerships [4] - The company has established a strategic agreement with Sun Yat-sen University to collaborate in the fields of gene editing and cell therapy [5] Group 3: Future Development and Collaboration - Future plans include building platforms based on project maturity and collaborating with domestic and international professional institutions [5] - The company aims to form a closed-loop health management system by integrating core technologies in key areas [5] - During the investor meeting, there was thorough communication without any disclosure of undisclosed significant information [6]